Delisting riskPopularity #5,220
BGM Group (BGM)
Combines pharmaceutical production with AI solutions and insurance services for Chinese markets.
$0.2650
After hours+0.01 (+5.12%)
At close$0.2521(−1.52%)
In millions of USD, except per-share figures
| In millions | Q2 FY24Mar 2024 | Q2 FY25Mar 2025 | Q4 FY25Sep 2025 | Q2 FY26Mar 2026 |
|---|---|---|---|---|
| Revenue | 13 | 14 | 24 | 24 |
| Cost of revenue | 11 | 12 | 21 | 21 |
| Gross profit | 1 | 2 | 3 | 3 |
| 2 | 4 | 13 | 4 | |
| Research & development | 0 | 1 | 0 | 0 |
| 2 | 4 | 13 | 4 | |
| Selling & marketing | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 4 | 0 | 0 |
| Operating income | −1 | −2 | −10 | −1 |
| 1 | −3 | −4 | −1 | |
| Interest income | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 |
| Other non-operating income | −2 | 0 | 0 | 0 |
| Income before tax | 0 | −5 | −15 | −2 |
| Income tax expense | 0 | −4 | 5 | 0 |
| Net income from continuing operations | 0 | −1 | −19 | −2 |
| Net income | 0 | −1 | −19 | −2 |
| EPS, basic | $0.05 | −$0.01 | −$0.15 | −$0.01 |
| EPS, diluted | $0.05 | −$0.03 | −$0.15 | −$0.01 |
| Weighted average shares, basic | 7 | 32 | 128 | 186 |
| Weighted average shares, diluted | 7 | 32 | 128 | 186 |
| EBITDA | −1 | −2 | −9 | 0 |
| Depreciation & amortization | 1 | 0 | 1 | 1 |
| EBIT | −1 | −2 | −10 | −1 |